Haematological, hepatic and renal alterations after repeated oral or intraperitoneal administration of monoisoamyl DMSA. I. Changes in male rats. 2002

Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
Division of Pharmacology and Toxicology, Defence Research and Development Establishment, Jhansi Road, Gwalior-474002, India.

Monoisoamyl 2,3-dimercaptosuccinic acid (MiADMSA), a vicinal thiol chelator, is gaining recognition recently as a better chelator than meso 2,3-dimercaptosuccinic acid (DMSA) in decreasing heavy metal burden in tissues because of its lipophilic character. There is, however, little information available on the toxicological properties of this chelator after repeated administration in animals. In the present study, we investigated the dose-dependent effect of MiADMSA on various biochemical parameters suggestive of alterations in haem biosynthesis and hepatic, renal and brain oxidative stress after 21 days of repeated intraperitoneal (i.p.) or oral (p.o.) administration to rats. The concentration of essential metals in blood and soft tissues was determined along with histopathological observations of hepatic and renal tissues. The results suggest that MiADMSA administration had no effect on blood delta-aminolevulinic acid dehydratase activity. However, an increase in zinc protoporphyrin and a decrease in haemoglobin levels were noted in animals given MiADMSA i.p. A moderate increase in serum alkaline phosphatase suggested mild hepatotoxicity at the highest dose (100 mg kg(-1), i.p.). This was confirmed by histopathological examinations, which identified basophilic stippling, granulation of the cytoplasm, haemorrhage and congestion. At the highest dose, levels of hepatic thiobarbituric acid reactive substance and oxidized glutathione were increased above those of control values. Levels of hepatic reduced glutathione were decreased. Taken together, these observations point to oxidative stress. In animals administered MiADMSA i.p. there was an increase in the brain malondialdehyde levels at the two higher doses (50 and 100 mg kg(-1)). Essential metal status revealed a significant effect of MiADMSA (p.o.) in increasing blood zinc while significantly decreasing the kidney zinc level. The most significant adverse effect of MiADMSA was on copper concentration, which showed significant depletion from almost all major organs. Magnesium levels in blood decreased but increased in liver of MiADMSA-administered rats. Histopathological observations of liver and kidneys suggest few moderate lesions. It can be concluded that repeated administration of MiADMSA is compromised with some mild toxic effect, particularly the loss of copper. The effects during oral administration are comparatively less pronounced than by the i.p. route.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D004113 Succimer A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them. DMSA,Dimercaptosuccinic Acid,2,3-Dimercaptosuccinic Acid,Butanedioic Acid, 2,3-Dimercapto-, (R*,S*)-Isomer,Chemet,Ro-1-7977,Succicaptal,Succimer Antimony Sodium Salt, (R*,S*)-Isomer,Succimer, (R*,R*)-(+,-)-Isomer,Succimer, Dipotassium Salt,Succimer, Disodium Salt,Succimer, Monosodium Salt,Succimer, Rhenium Salt,Succimer, Tin Salt,Tin Dimercaptosuccinate,meso-Dimercaptosuccinic Acid,2,3 Dimercaptosuccinic Acid,Acid, 2,3-Dimercaptosuccinic,Acid, Dimercaptosuccinic,Acid, meso-Dimercaptosuccinic,Dimercaptosuccinate, Tin,Dipotassium Salt Succimer,Disodium Salt Succimer,Monosodium Salt Succimer,Rhenium Salt Succimer,Ro 1 7977,Ro17977,Tin Salt Succimer,meso Dimercaptosuccinic Acid
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
January 2003, Journal of applied toxicology : JAT,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
July 2008, Toxicology and applied pharmacology,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
January 2008, Oxidative medicine and cellular longevity,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
January 1993, Annals of clinical and laboratory science,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
January 2005, Environmental toxicology and pharmacology,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
April 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
March 2012, Toxicology and industrial health,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
August 2010, Fundamental & clinical pharmacology,
Ashish Mehta, and G M Kannan, and S N Dube, and B P Pant, and S C Pant, and S J S Flora
September 1982, The British journal of nutrition,
Copied contents to your clipboard!